Biogen Inc.’s controversial Alzheimer’s drug Aduhelm produced brain swelling in 35% of patients who took the approved dose, although most didn’t experience symptoms, company researchers said in a study.
Biogen Inc.’s controversial Alzheimer’s drug Aduhelm produced brain swelling in 35% of patients who took the approved dose, although most didn’t experience symptoms, company researchers said in a study.